Edwards Lifesciences' 2027 Guidance Seen Leaving Room for Upward Revisions, RBC Says

MT Newswires Live01:38

Edwards Lifesciences' (EW) initial 2027 organic revenue growth guidance is expected to be relatively conservative at 9% to 11%, with room for upward revisions during the year, RBC Capital Markets said in a Thursday note.

The firm noted Edwards started 2026 with revenue growth guidance of 8% to 10% before raising it to about 11.5% on strong portfolio momentum.

RBC expects several potential growth drivers in 2027, including the first full-year benefit of the updated US national coverage determination for transcatheter aortic valve replacement, higher procedure volumes, and other emerging opportunities.

"We believe 2027 expectations include continued growth resulting in significant cash flows to fund future internal and external opportunities and share buybacks," the report said.

RBC reiterated its outperform rating and $115 price target on Edwards Lifesciences.

Price: 103.30, Change: -0.58, Percent Change: -0.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment